Candia, Jimboy M.

HRN: 20-48-83  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/15/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/15/2023
01/22/2023
IVTT
165mg
Q24
PCAP
Waiting Final Action 

Indication:  Empiric    Type of Infection:  PneumoniaSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: